Target intelligence / Profile preview

Rat alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR) (α3β4 nAChR)

Target
α3β4 nAChR
Molecular classification
Ion channel, Receptor, Nicotinic acetylcholine receptor, Cys-loop ligand-gated ion channel
01

Overview

The rat alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR) is a pentameric ligand-gated ion channel composed of α3 and β4 subunits [2, 4]. It is primarily expressed in the autonomic ganglia, adrenal medulla, and specific central nervous system regions such as the medial habenula and interpeduncular nucleus [2, 11, 13]. In the periphery, it facilitates fast excitatory synaptic transmission within the autonomic nervous system, regulating involuntary organ functions [8, 10]. Centrally, the α3β4 subtype plays a critical role in the reward, aversion, and withdrawal pathways associated with substance use disorders [3, 6, 11]. Genetic variations in the CHRNA3-CHRNA5-CHRNB4 gene cluster are strongly linked to nicotine and alcohol dependence, and similar pathways are studied in rat models to develop anti-addictive therapies [6, 12, 13]. Pharmacological modulation of this receptor, particularly through antagonists or partial agonists like 18-methoxycoronaridine (18-MC) and varenicline, has shown promise in reducing drug-seeking behavior for nicotine, cocaine, and alcohol [3, 6, 7]. However, therapeutic targeting is challenged by potential autonomic side effects due to the receptor's widespread expression in the peripheral nervous system [2, 5]. Research continues to focus on developing selective ligands that can cross the blood-brain barrier while minimizing peripheral ganglionic activity [12, 13].

Other names
Ganglion-type nicotinic receptorGanglionic nAChRalpha3beta4* nAChRNeuronal acetylcholine receptor subunit alpha-3/beta-4
02

Mechanism of action

Agonist, Partial agonist, Non-competitive antagonist, Negative allosteric modulator, Channel blocker

03

Biological functions

Signal transductionSynaptic transmissionAutonomic nervous system regulationNeurotransmitter release
04

Disease associations

AddictionNicotine dependenceAlcohol use disorderCocaine use disorderAutonomic dysfunction
05

Safety considerations

Autonomic side effects (blood pressure and heart rate changes)Gastrointestinal distressPotential for seizuresOff-target effects on other nAChR subtypes
06

Interacting drugs

Nicotine

14 more in the full profile.

07

Biomarkers

CHRNA3-CHRNA5-CHRNB4 gene cluster polymorphismsReceptor occupancy (PET imaging)

Beyond the preview

Go deeper on Rat alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR) (α3β4 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rat alpha-3 beta-4 nicotinic acetylcholine receptor (α3β4 nAChR) (α3β4 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call